FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2962766175> ?p ?o ?g. }

• W2962766175 endingPage "39" @default.
• W2962766175 startingPage "33" @default.
• W2962766175 abstract "Background. There is limited information about impact of additional chromosome aberrations (ACA) on the efficacy of the 2nd line nilotinib therapy. Objective. The aim of the study was to analyze significance of ACAs for the outcome after second line tyrosine kinase inhibitors (TKI) therapy with nilotinib in the chronic myeloid leukemia (CML) patients, who experienced previous imatinib therapy failure. Methods. The CML patients in chronic phase treated with nilotinib after imatinib failure were analyzed for outcomes. Results. Among a total of 114 patients, 18 patients (15.8%) had ACAs at the beginning of the 2nd line therapy with nilotinib. Seven patients (38.9%) of 18 had variant translocations and 11 patients (61.1%) had other chromosomal abnormalities in addition to t(9;22), known as clonal evolution. Complete cytogenetic response (CCR) at 12 months was achieved in 37.5%, 42.8% and 45.5% (p=0.842) of patients with classic t(9;22) translocation, variant translocations and ACAs respectively. In the patients with variant translocations t(9;V;22) or clonal evolution treated with nilotinib after the imatinib failure, the CCR and major molecular response (MMR), event free survival (EFS), progression free survival (PFS) and overall survival (OS) rates did not differ from those in the CML patients with t(9;22) only. At the same time quantitative characteristics of leukemic and ACA clones had prognostic value for CCR. The increased number of Ph-positive cells and the number of cells with the ACA at the start of nilotinib therapy reduced the probability of CCR. Conclusions. Higher nilotinib inhibitory activity compare with imatinib allows us to overcome imatinib resistance in the CML patients regardless of the ACA presence at the beginning of nilotinib therapy." @default.
• W2962766175 created "2019-07-30" @default.
• W2962766175 creator A5049753301 @default.
• W2962766175 creator A5060567127 @default.
• W2962766175 creator A5075748896 @default.
• W2962766175 creator A5090487357 @default.
• W2962766175 date "2019-07-11" @default.
• W2962766175 modified "2023-10-15" @default.
• W2962766175 title "SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS" @default.
• W2962766175 cites W1509074151 @default.
• W2962766175 cites W1965429870 @default.
• W2962766175 cites W1968747503 @default.
• W2962766175 cites W1970012935 @default.
• W2962766175 cites W1973021154 @default.
• W2962766175 cites W1978668514 @default.
• W2962766175 cites W2000123759 @default.
• W2962766175 cites W2033661259 @default.
• W2962766175 cites W2087562706 @default.
• W2962766175 cites W2095235463 @default.
• W2962766175 cites W2106575058 @default.
• W2962766175 cites W2153715492 @default.
• W2962766175 cites W2276472705 @default.
• W2962766175 cites W2314938037 @default.
• W2962766175 cites W2321560918 @default.
• W2962766175 cites W2762030175 @default.
• W2962766175 cites W2780279106 @default.
• W2962766175 doi "https://doi.org/10.11603/ijmmr.2413-6077.2019.1.10305" @default.
• W2962766175 hasPublicationYear "2019" @default.
• W2962766175 type Work @default.
• W2962766175 sameAs 2962766175 @default.
• W2962766175 citedByCount "0" @default.
• W2962766175 crossrefType "journal-article" @default.
• W2962766175 hasAuthorship W2962766175A5049753301 @default.
• W2962766175 hasAuthorship W2962766175A5060567127 @default.
• W2962766175 hasAuthorship W2962766175A5075748896 @default.
• W2962766175 hasAuthorship W2962766175A5090487357 @default.
• W2962766175 hasBestOaLocation W29627661751 @default.
• W2962766175 hasConcept C104317684 @default.
• W2962766175 hasConcept C121608353 @default.
• W2962766175 hasConcept C126322002 @default.
• W2962766175 hasConcept C138626823 @default.
• W2962766175 hasConcept C143998085 @default.
• W2962766175 hasConcept C2777413986 @default.
• W2962766175 hasConcept C2777583451 @default.
• W2962766175 hasConcept C2778729363 @default.
• W2962766175 hasConcept C2778820342 @default.
• W2962766175 hasConcept C2778904597 @default.
• W2962766175 hasConcept C54355233 @default.
• W2962766175 hasConcept C71924100 @default.
• W2962766175 hasConcept C86803240 @default.
• W2962766175 hasConceptScore W2962766175C104317684 @default.
• W2962766175 hasConceptScore W2962766175C121608353 @default.
• W2962766175 hasConceptScore W2962766175C126322002 @default.
• W2962766175 hasConceptScore W2962766175C138626823 @default.
• W2962766175 hasConceptScore W2962766175C143998085 @default.
• W2962766175 hasConceptScore W2962766175C2777413986 @default.
• W2962766175 hasConceptScore W2962766175C2777583451 @default.
• W2962766175 hasConceptScore W2962766175C2778729363 @default.
• W2962766175 hasConceptScore W2962766175C2778820342 @default.
• W2962766175 hasConceptScore W2962766175C2778904597 @default.
• W2962766175 hasConceptScore W2962766175C54355233 @default.
• W2962766175 hasConceptScore W2962766175C71924100 @default.
• W2962766175 hasConceptScore W2962766175C86803240 @default.
• W2962766175 hasIssue "1" @default.
• W2962766175 hasLocation W29627661751 @default.
• W2962766175 hasOpenAccess W2962766175 @default.
• W2962766175 hasPrimaryLocation W29627661751 @default.
• W2962766175 hasRelatedWork W114456681 @default.
• W2962766175 hasRelatedWork W1974135663 @default.
• W2962766175 hasRelatedWork W2025935458 @default.
• W2962766175 hasRelatedWork W2069378056 @default.
• W2962766175 hasRelatedWork W2114266850 @default.
• W2962766175 hasRelatedWork W2117422006 @default.
• W2962766175 hasRelatedWork W2120868842 @default.
• W2962766175 hasRelatedWork W2995128897 @default.
• W2962766175 hasRelatedWork W3206268020 @default.
• W2962766175 hasRelatedWork W4253578959 @default.
• W2962766175 hasVolume "5" @default.
• W2962766175 isParatext "false" @default.
• W2962766175 isRetracted "false" @default.
• W2962766175 magId "2962766175" @default.
• W2962766175 workType "article" @default.